
We claim:


1. A combination of a compound of formula I:



(I)

or a pharmaceutically acceptable salt thereof; and an agent selected from GDC-0973, ~~PD-0325901,~~ or a pharmaceutically acceptable salt thereof, for the therapeutic treatment of a cancer, wherein the cancer is melanoma, colorectal cancer or lung cancer ~~hyperproliferative disorder~~.

2. Use of a compound of formula I:



(I)

or a pharmaceutically acceptable salt thereof; and an agent selected from GDC-0973, ~~PD-0325901,~~ or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for ~~the therapeutic treatment of a~~ treating cancer, wherein the cancer is melanoma, colorectal cancer or lung cancer~~hyperproliferative disorder~~.

~~3. The use of claim 2, wherein the hyperproliferative disorder is cancer.~~

~~4.~~3. The use of claim ~~3~~2, wherein the cancer is associated with PTEN mutation.

~~5.~~4. The use of claim ~~3~~2, wherein the cancer is associated with AKT mutation, overexpression or amplification.

~~6.~~5. The use of claim ~~3~~2, wherein the cancer is associated with PI3K mutation.

~~7.~~6. The use of claim ~~3~~2, wherein the cancer is associated with Her2/ErbB2 amplification.

~~8. The use of any one of claims 3-7, wherein cancer is selected from, mesothelioma, endometrial, pancreatic, breast, lung, ovarian, prostate, melanoma, gastric, colon, renal, head and neck, and glioma.~~

~~9.~~7. The use of any one of claims 2-~~8~~6, wherein a compound of formula I, or a pharmaceutically acceptable salt thereof, is to be administered in combination with GDC-0973.

~~10. The use of any one of claims 2-8, wherein a compound of formula I, or a pharmaceutically acceptable salt thereof, is to be administered in combination with PD-0325901.~~

~~11.~~8. The use of any one of claims 2-~~10~~7, wherein the compound of formula I or the salt thereof is to be administered simultaneously with the one or more agents.

~~12.~~9. The use of any one of claims 2-~~10~~7, wherein the compound of formula I or the salt and the one or more agents are to be administered sequentially.

~~13.~~10. The use of any one of claims 2-~~10~~7, wherein administration of the one or more agents begins about 1 to about 10 days before administration of the combination.

~~14.~~11. The use of any one of claims 2-~~10~~7, wherein administration of the compound of formula I or the salt thereof begins about 1 to about 10 days before administration of the combination.

~~15.~~12. The use of any one of claims 2-~~10~~7, wherein administration of the compound of formula I or the salt thereof and administration of the one or more agents begins on the same

day.

~~16. The use of any one of claims 2-8, wherein a compound of formula I, or a pharmaceutically acceptable salt thereof, is to be administered in combination with GDC-0973, and the cancer is pancreatic.~~

~~17.~~13. The use of any one of claims 2-~~8~~12, wherein a compound of formula I, or a pharmaceutically acceptable salt thereof, is to be administered in combination with GDC-0973, and the cancer is ~~non-small cell~~ lung cancer.

14. The use of claim 13, wherein the lung cancer is non-small cell lung cancer.


~~18. The use of any one of claims 2-8, wherein a compound of formula I, or a pharmaceutically acceptable salt thereof, is to be administered in combination with GDC-0973, and the cancer is breast.~~

~~19.~~15. The use of any one of claims 2-~~8~~12, wherein a compound of formula I, or a pharmaceutically acceptable salt thereof, is to be administered in combination with GDC-0973, and the cancer is colon.

~~20.~~16. The use of any one of claims 2-~~8~~12, wherein a compound of formula I, or a pharmaceutically acceptable salt thereof, is to be administered in combination with GDC-0973, and the cancer is melanoma.

17. The use of claim 16, wherein the melanoma is metastatic melanoma.


~~21. The combination of a) a compound of formula I~~



~~(I)~~

~~or a pharmaceutically acceptable salt thereof; and b) one or more agents selected from GDC-0973, PD-0325901, or a pharmaceutically acceptable salt thereof for treating a hyperproliferative disorder.~~


~~22.~~18. The combination of a) a compound of formula I



(I)

or a pharmaceutically acceptable salt thereof; and b) one or more agents selected from GDC-0973, ~~PD-0325901,~~ or a pharmaceutically acceptable salt thereof for treating ~~a disease or condition~~ cancer modulated by AKT kinase, wherein the cancer is melanoma, colorectal cancer or lung cancer.


~~23. The use of the combination of a compound of formula I~~



~~(I)~~

~~or a pharmaceutically acceptable salt thereof and GDC-0973, PD-0325901, or a pharmaceutically acceptable salt thereof in the preparation of a medicament for the treatment of a hyperproliferative disorder in a mammal.~~


~~24.~~19. A kit comprising a compound of formula I



(I)

or a pharmaceutically acceptable salt thereof, a container, and a package insert or label indicating the administration of the compound of formula I with one or more agents selected from GDC-0973, ~~PD-0325901,~~ or a pharmaceutically acceptable salt thereof for treating a cancer, wherein the cancer is melanoma, colorectal cancer or lung cancer ~~hyperproliferative disorder~~.


~~25.~~20. A product comprising a compound having formula I



(I)

or a pharmaceutically acceptable salt thereof, and one or more agents selected GDC-0973, ~~PD-0325901,~~ or a pharmaceutically acceptable salt thereof; as a combined preparation for separate, simultaneous or sequential use in the treatment of cancer, wherein the cancer is melanoma, colorectal cancer or lung cancer~~a hyperproliferative disorder~~.

~~26. Use of a combination of a compound of formula I:~~



(I)

or a pharmaceutically acceptable salt thereof; and another agent selected from GDC-0973, PD-0325901, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating a hyperproliferative disorder in a mammal.